ORPHAZYME EXPECTS TO ANNOUNCE RESULTS OF FULL DATA SET FOR NIEMANN-PICK DISEASE TYPE C (NPC) PHASE II/III TRIAL IN Q1 2019

Copenhagen, December 10, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that the Company expects to announce the results of the full data set for the clinical Phase II/III trial in NPC in Q1 2019.

PUBLICATION OF MANUSCRIPT ON PRECLINICAL PROOF-OF-CONCEPT OF ARIMOCLOMOL IN GAUCHER DISEASE

Copenhagen, November 27, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that a manuscript providing preclinical Proof-of-Concept for its lead compound, arimoclomol, in Gaucher disease was published in the peer-reviewed scientific journal EBioMedicine. The manuscript details how the heat-shock amplifier, arimoclomol, improves the refolding, maturation, and lysosomal activity of glucocerebrosidase (GCase), the enzyme deficient in Gaucher disease and linked to Parkinson’s disease.

ORPHAZYME ENDORSES PATIENT ADVOCACY CONSENSUS GUIDELINES, HIGHLIGHTS IMPORTANCE OF COLLABORATION WITH PATIENT COMMUNITIES

Copenhagen, October 15, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced the company’s endorsement of published guidelines to support interactions with rare disease patient advocacy organizations.

ORPHAZYME REPORTS ENCOURAGING ARIMOCLOMOL CLINICAL TRIAL TOP-LINE DATA IN NIEMANN-PICK DISEASE TYPE C (NPC)

Copenhagen, September 28, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced encouraging top-line results for its clinical Phase II/III trial with orally administered arimoclomol for the treatment of patients with Niemann-Pick disease Type C (NPC).

ORPHAZYME TO PRESENT AT 25TH NPUK ANNUAL FAMILY CONFERENCE 2018

Copenhagen, September 20, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that Thomas Kirkegaard Jensen, Chief Scientific Officer at Orphazyme, will be presenting at the 25th NPUK Annual Family Conference 2018 in Wyboston, Bedfordshire, UK, on September 21-22, 2018.

ORPHAZYME TO PRESENT AT INVESTORDAGEN 2018

Copenhagen, September 18, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that Anders Hinsby, Chief Executive Officer at Orphazyme, will be presenting at Dansk Aktionærforening’s InvestorDagen in Copenhagen, Denmark, today, September 18, 2018 at 10.20 AM CET.

For free participation, please visit www.InvestorDagen.dk and use the code VIPOrphazyme2018.